Continued Due Diligence Report

Can-Fite Biopharma Fast Track Designation Raises Prospects For Liver Cancer Treatment

NEW YORK, NY / ACCESSWIRE / September 21, 2015 / Shares of Can-Fite BioPharma Ltd. (NYSE-MKT: CANF) rallied 49% on Friday. The stock appears ready to build on last week’s gains following the FDA’s decision to grant Fast Track Designation to the company’s promising liver cancer treatment.

Broad Street Alerts continues its coverage of Can-Fite Biopharma that was initiated November 19, 2014 with a due diligence report that all shareholders will want to read.

A chartered financial analyst produces a due diligence report on CANF that includes an explanation of why this decision is so important for the company; along with a brief company overview, market overview, financial review, analyst summary, and recommendation. You can view this report by using the following link at no cost.

http://bit.ly/CANF_Due_Diligence_Report

About Broad Street Alerts:

We make the connection between sophisticated investors and high quality micro and small cap companies. An issuer of reports that provide a straightforward assessment of the profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

Safe Harbor Statement:

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management’s own knowledge and assessment of the Company’s industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements

Compliance Procedure:

Content is researched, written and reviewed on a best-effort basis by a 3rd party chartered financial analyst. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us. This report was prepared for informational purposes only. A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and coinciding reports. For more information and services provided beyond this press release please use contact information provided below.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

Contact:

editor@broadstreetalerts.com

SOURCE: Broad Street Alerts

ReleaseID: 432095